REG - Solvonis Therapeutic - AGM Statement

Solvonis TherapeuticsAnnouncement

27/06/2025 14:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250627:nRSa8187Oa&default-theme=true

RNS Number : 8187O  Solvonis Therapeutics PLC  27 June 2025

27 June 2025
Solvonis Therapeutics plc

("Solvonis" or the "Company")

 

AGM statement and strategic update

Solvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical
company developing novel medicines for addiction and mental health disorders,
announces that all resolutions proposed at its Annual General Meeting ("AGM")
held earlier today were duly passed. A summary of the resolutions is provided
at the end of this announcement.

This year's AGM marks a significant milestone in the Company's growth
trajectory. Following the successful completion of the acquisition of Awakn
Life Sciences on 28 May 2025, Solvonis has rapidly established itself as a
leading European innovator in the development of precision neuropsychiatric
therapeutics.

The combined company now benefits from a high-quality pipeline of preclinical
and clinical-stage assets targeting alcohol use disorder, post-traumatic
stress disorder, and other complex neuropsychiatric conditions. These
programmes, including lead candidate SVN-001, are underpinned by translational
science, real-world evidence, and a regulatory strategy aligned with expedited
pathways in key jurisdictions.

Integration activities are progressing in line with plan, with a focus on
operational efficiency, disciplined capital deployment, and preparing lead
programmes for Phase 3 readiness and partnering opportunities. Solvonis
continues to advance a virtual biotech model, supported by a lean team and an
expanding network of expert collaborators and CROs.

Anthony Tennyson, CEO of Solvonis Therapeutics, commented: "Today's AGM
reflects strong shareholder support for our vision and execution. With the
acquisition of Awakn now complete, we are strategically positioned to lead in
transforming the treatment landscape for substance use and treatment-resistant
mental health disorders across Europe and beyond. We are focused on delivering
value through rigorous development, targeted commercial strategy, and
partnerships that extend our reach and impact."

The Board remains committed to building a capital-efficient, data-driven, and
licensing-led business capable of delivering meaningful therapeutic advances
and long-term value creation.

Further updates on programme progress and strategic initiatives will be
provided in due course.

As noted, all resolutions proposed at the meeting were passed. The results of
voting on each resolution are summarised below:

 Resolution    Votes for    For %   Votes against  Against %  Votes total  Votes withheld
 Resolution 1  600,321,074  99.90%  572,816        0.10%      600,893,890  2,000
 Resolution 2  565,318,574  99.90%  572,816        0.10%      565,891,390  35,004,500
 Resolution 3  599,379,529  99.75%  1,514,361      0.25%      600,893,890  2,000
 Resolution 4  564,851,874  99.82%  1,039,516      0.18%      565,891,390  35,004,500
 Resolution 5  564,851,874  99.82%  1,039,516      0.18%      565,891,390  35,004,500
 Resolution 6  599,846,229  99.83%  1,047,661      0.17%      600,893,890  2,000
 Resolution 7  564,377,029  93.92%  36,516,861     6.08%      600,893,890  2,000
 Resolution 8  600,321,074  99.90%  572,816        0.10%      600,893,890  2,000

 

Notes:

1)    Resolutions 1 to 6 were passed as ordinary resolutions. Resolution 7
and 8 were passed as special resolutions.

2)    A vote withheld is not a vote in law and is not counted in the
calculation of the proportion of votes "For" or "Against" any of the
resolutions.

3)    As at the date of the GM, the Company's issued share capital
consisted of 5,908,770,690 ordinary shares of £0.001 each.

 

Enquiries:

Solvonis Therapeutics plc

Anthony Tennyson, CEO & Executive Director

anthony@solvonis.com

Allenby Capital Limited (Financial Adviser and Joint Broker)

Nick Naylor / Nick Athanas / Ashur Joseph (Corporate Finance)

Guy McDougall (Sales & Corporate Broking)

+44 (0) 20 3328 5656

Singer Capital Markets (Joint Broker)

Phil Davies

+44 (0) 20 7496 3000

About Solvonis Therapeutics plc

Solvonis Therapeutics plc (LSE: SVNS) is a clinical-stage biopharmaceutical
company developing novel medicines for addiction and mental health disorders.
Headquartered in London and listed on the main market of the London Stock
Exchange, Solvonis is advancing a differentiated pipeline of repurposed and
novel compounds targeting high-burden neuropsychiatric conditions with
significant unmet need.

The Company's lead programmes address Alcohol Use Disorder (AUD) and
Post-Traumatic Stress Disorder (PTSD)-conditions affecting over 80 million
people across the UK, US, and EU4. Its lead asset, SVN-001, is currently in
Phase 3 for severe AUD in Europe and the UK. SVN-002 is preparing for a Phase
2b trial in the US targeting moderate to severe AUD. Solvonis also has a
preclinical PTSD programme leveraging novel serotonin-dopamine modulators
designed to enhance pro-social behaviour and long-term outcomes.

In addition, Solvonis is advancing an AI-supported discovery platform built on
a proprietary CNS compound library, with initial focus on depression and
stimulant use disorders. This initiative expands the Company's R&D
pipeline into earlier-stage innovation while maintaining strategic focus on
comorbid and underserved neuropsychiatric conditions.

With a capital-efficient model, dual development strategy, and near-term
partnering opportunities, Solvonis is positioned to generate value through
innovation in neuropsychiatry.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGMSEWFDWEISEDM